Cardiovascular BioTherapeutics, Inc. Engages The Bruckner Group To Find A Joint Commercialization Partner For Its FGF-1 Protein Treatment for Cardiovascular Disease Patients

WAKEFIELD, Mass.--(BUSINESS WIRE)--The Bruckner Group is pleased to announce that CardioVascular BioTherapeutics, Inc. (“CVBT”) (NASDAQ:CVBT.OB) has engaged The Bruckner Group (BGI) to find a joint commercialization partner for CVBT’s cardiovascular disease drug candidates, based on Fibroblast Growth Factor-1 (FGF-1). CVBT’s FGF-1 presents the significant possibility of becoming the breakthrough angiogenic therapy that researchers have elusively sought for the last 10 years for patients with coronary artery disease (CAD). If data from the ongoing clinical trials continues to produce results consistent with previous data and patient outcomes, BGI believes that within three years of regulatory approval, CVBT’s new drug will produce worldwide revenues in the high ten-figure range.